Investors looking for high-risk, high-reward opportunities often turn to stocks trading under $1. These penny stocks, while volatile, can offer significant upside potential. Here are five (5) stocks currently trading under $1 on major exchanges that analysts believe have substantial growth prospects:

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) A leader in genomic medicine, Sangamo is developing gene therapies and CAR-Treg therapies for serious diseases such as Fabry disease and hemophilia A. The company has several clinical-stage product candidates and strategic partnerships with major pharmaceutical companies like Biogen, Pfizer, and Novartis​

FTC Solar, Inc. (NASDAQ: FTCI) FTC Solar specializes in solar tracker systems and engineering services, offering solutions that improve the efficiency of solar installations. With a diverse customer base and operations in multiple regions, FTC Solar is positioned well for growth in the renewable energy sector​.

Catheter Precision Inc. (NYSE AMERICAN: VTAK) focuses on developing innovative medical devices for cardiac procedures. Its flagship product, VIVO™ (View Into Ventricular Onset), enhances the accuracy of cardiac ablation by mapping ventricular arrhythmias pre-surgery, leading to improved patient outcomes.

Spruce Biosciences, Inc. (NASDAQ: SPRB) This biopharmaceutical company focuses on developing therapies for rare endocrine disorders, such as congenital adrenal hyperplasia and polycystic ovary syndrome. With multiple products in Phase 2 clinical trials and strategic collaborations, Spruce Biosciences has substantial growth potential​.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Significant based on their advancements in synthetic biology. Ginkgo Bioworks is leveraging its platform to create custom organisms for a variety of industries, including pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative approach and strategic partnerships position it for strong future growth.

These five (5) stocks have been identified based on their innovative products, strong clinical or technological advancements, and significant market potential, making them compelling options for investors looking for high-risk, high-reward opportunities.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com